Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor  The study met prima...

May 26, 2023 | Friday | News
Takeda and HUTCHMED's Fruquintinib NDA for Metastatic Colorectal Cancer Gets Priority Review

— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...

May 26, 2023 | Friday | News
Catalent Strengthens Cryogenic Capabilities in Shiga, Japan, Facility for Cell and Gene Therapy

State-of-the-art cryogenic freezers alongside material transfer equipment have been installed that are designed to retain the integrity of investigational ...

May 25, 2023 | Thursday | News
Rakuten Medical Initiates Global Phase 3 Trial of Alluminox™ Treatment for Head and Neck Cancer in India

The Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical...

May 23, 2023 | Tuesday | News
Nexcella Reports 100% Response Rate in NXC-201 Clinical Trial for DARZALEX-Relapsed/Refractory AL Amyloidosis

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (...

May 22, 2023 | Monday | News
Everest Medicines Completes Patient Enrollment in Phase 3 Trial of Etrasimod in Asia

"We are very pleased to achieve full patient enrollment in Asia ahead of schedule, which brings Everest an important step closer to offering etrasimod to p...

May 17, 2023 | Wednesday | News
Transcenta Reports Promising Phase I Data of TST002 in Chinese Patients with Reduced Bone Mineral Density

Transcenta in-licensed the Great China rights of Blosozumab from Eli Lilly and Company ("Eli Lilly") for development and commercialization in Greater China...

May 17, 2023 | Wednesday | News
Boehringer Ingelheim and Zealand Pharma's Phase II Trial Shows 14.9% Weight Loss in Obesity

Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardi...

May 11, 2023 | Thursday | News
Moleculin updates ongoing clinical trials and upcoming milestones

Recently completed first cohort in Phase 1b/2 trial evaluating Annamycin in combination with cytarabine (Ara-C) for the treatment of acute myeloid leukemia...

May 11, 2023 | Thursday | News
China Approves KN026 + Chemotherapy Phase III Study for Breast Cancer Treatment

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for t...

May 09, 2023 | Tuesday | News
Singlera Genomics' PDACatch Gets FDA Breakthrough Designation for Pancreatic Cancer Liquid Biopsy

Pancreatic adenocarcinoma (PDAC) is one of the most deadly forms of cancer, in part due to the majority of diagnoses being late-stage; the five-year surviv...

May 09, 2023 | Tuesday | News
Soligenix Reports Positive Results for HyBryte™ Compatibility Study in Cutaneous T-Cell Lymphoma Treatment

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...

May 05, 2023 | Friday | News
Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial

Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced positive results today from the pedia...

May 05, 2023 | Friday | News
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

OnKai, a US-based technology company, combines public healthcare and medical innovation experience with complex process digitalization, design thinking, an...

May 05, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close